title: Recent developments in the treatment of Parkinson's disease.
abstract: An acceptable level of motor improvement allows the patient to do the physical tasks necessary for independent functioning. Patients achieve this level of improvement, on an average, with less than six tablets daily of 25/100 carbidopa/L-dopa. Bromocriptine mesylate, one of the dopamine agonist drugs, may be used in patients without the concomitant use of other agents. However, my experience suggests it is more effective in conjunction with carbidopa and L-dopa.
authors.forename: M
authors.initials: M
authors.lastname: Greer
mesh_terms: D000368:Aged; D000375:Aging; D000547:Amantadine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005082:Physical Exertion
chemical_list: D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D007980:Levodopa; D000547:Amantadine